In ensuring the continuous access of prescription drugs to individuals vulnerable to COVID-19, the FDA Circular No. 2020-007 was issued to provide guidelines to consumers and health providers on the use of electronic prescription.
Due to the regular updates to the quarantine status of the different cities and municipalities and in the event that the imposed quarantine is lifted, the provisions of this Circular may still deemed be applicable and necessary by the public’s interest.
In view of the foregoing, the effectivity of FC No. 2020-007 shall be until 31 December 2020, subject for extension upon the review of this Office.
Attachment:-> FDA Circular No.2020-007-A